MARKET WIRE NEWS

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Source: SeekingAlpha

2025-02-13 23:45:02 ET

Bio-Rad Laboratories, Inc. (BIO)

Q4 2024 Earnings Conference Call

February 13, 2025 17:00 ET

Company Participants

Edward Chung - Vice President of Investor Relations

Jon DiVincenzo - President & Chief Operating Officer

Roop Lakkaraju - Executive Vice President & Chief Financial Officer

Norman Schwartz - Chairman of the Board, President & Chief Executive Officer

Conference Call Participants

Dan Leonard - UBS

Brandon Couillard - Wells Fargo

Jack Meehan - Nephron Research

Conor McNamara - RBC Capital Markets

Tycho Peterson - Jefferies

Presentation

Operator

Thank you for standing by. My name is Prila [ph] and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad Fourth Quarter and Full Year 2024 Results Conference Call and Webcast. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

I would now like to turn the conference over to Edward Chung, Head of Investor Relations. You may begin.

Edward Chung

Thanks, operator. Good afternoon everyone and thank you for joining us. Today, we will review the fourth quarter and full year 2024 financial results and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; Jon DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer.

Before we begin our review, I would like to remind everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals and expectations. You should not place undue reliance on these forward-looking statements and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP financials, including net income and diluted earnings per share which are financial measures that are not defined under generally accepted accounting principles. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release.

With that, I will now turn the call over to our Chief Operating Officer, Jon DiVincenzo....

Read the full article on Seeking Alpha

For further details see:

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
Bio-Rad Laboratories Inc. Class A

NASDAQ: BIO

BIO Trading

1.56% G/L:

$281.74 Last:

236,389 Volume:

$281.82 Open:

VWAV Ad 300

BIO Latest News

BIO Stock Data

$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App